RE:heratechnologies, Mackie Research says"The analyst adds that although TH’s sales for Egrifta, the company’s injectable drug used to reduce abdominal fat in patients with HIV and lipodystrophy, were largely in line with his estimates for Q1 ($9.0 million versus Uddin’s $8.4 million), sales are likely to be flat for 2019."
First, $9 million is greater than $8.4 million.
Second, he is expecting flat sales? The only way that occurs is if some prescribers wait until the Fall and F4.
So, it seems it would be possible for overall sales to stagnate somewhat but it is not really intellectually honest to describe the sales as flat.
The new campaign, new formulation and change in the view from cosmetic (whether warranted or not) to therapeutic drug will affect scripts. I expect scripts to really jump in the Fall as we will have all the NASH data in hand and the above changes will be in place.
For now, we wait for the results of tomorrow's meeting......
bfw